Mangrove Partners Eiger Bio Pharmaceuticals, Inc. Transaction History

Mangrove Partners

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$7.98 - $12.29 $8.72 Million - $13.4 Million	-1,092,394 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$7.96 - $12.42 $1.15 Million - $1.8 Million	144,542 Added 15.25%	1,092,394 $8.89 Million
Q2 2020 Aug 14, 2020	BUY	$5.4 - $13.37 $1.43 Million - $3.53 Million	264,024 Added 38.61%	947,852 $9.1 Million
Q1 2020 May 15, 2020	SELL	$4.91 - $14.7 $802,568 - $2.4 Million	-163,456 Reduced 19.29%	683,828 $4.65 Million
Q2 2019 Aug 14, 2019	BUY	$9.54 - $14.96 $2.86 Million - $4.49 Million	300,000 Added 54.82%	847,284 $8.98 Million
Q4 2018 Feb 14, 2019	BUY	$8.63 - $12.4 $4.72 Million - $6.79 Million	547,284 New	547,284 $5.56 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $76.1M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.